In this Issue
Researchers share their insights into the disease, its diagnosis, and its treatment.
CHIEF MEDICAL EDITOR’S PAGE
By Steven D. Vold, MD
By Pradeep Y. Ramulu, MD, MHS, PhD
This technology has become a valuable tool for diagnosing, treating, and conducting research on angle closure.
By Robert M. Feldman, MD
By Jeffrey Tennant, MD; Douglas E. Gaasterland, MD; E. Kenneth Sullivan, PhD; and Paul VanVeldhuisen, PhD
Achieving cost-effective, sustainable care in this region.
By Milad Moddaber, MSc, and Karim F. Damji, MD, FRCSC, MBA
How dynamic pulsatile mechanisms determine aqueous outflow.
By Murray Johnstone, MD
Its role in modulating aqueous humor outflow and IOP.
By Swarup S. Swaminathan; Dong-Jin Oh, PhD; Min Hyung Kang, PhD; Ramez I. Haddadin, MD; Guadalupe Villarreal Jr, MD; Marc Töteberg-Harms, MD; Ayan Chatterjee; and Douglas J. Rhee, MD
What likely contributes to the pathogenesis of this disease?
By Haiyan Gong, MD, PhD
Current understanding and methods of measurement.
By Carol B. Toris, PhD
Methods by which to modulate flow through this pathway.
By Arthur J. Sit, SM, MD
Update on OCT technology for visualizing Schlemm canal.
By Larry Kagemann, PhD, and Joel S. Schuman, MD
Why you may not get the IOP low enough yet.
By David L. Epstein, MD, MMM
These processes and the ophthalmologist’s ability to control them ultimately determine the long-term success of all glaucoma surgery.
By Alastair Lockwood, BM, BChir, MRCOphth, and Sir Peng Tee Khaw, PhD, FRCP, FRCS, FRCOphth, CBiol, FSB, FRCPath, FARVO, FMedSci
Research is revealing much about the inheritance of disease. Genetic testing is useful for patients with early-onset glaucoma and for some families with multiple members affected by normal-tension and primary open-angle.
By Janey L. Wiggs, MD, PhD
Three surgeons discuss the clinical scenarios in which they prescribe these drugs.
By L. Jay Katz, MD; Robert J. Noecker, MD, MBA; and James C. Tsai, MD, MBA
The second installment in this three-part series focuses on sustainable, responsible growth.